74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Bluebird Bio Inc
Closed
4.12 0.73
Overview
Share price change
24h
Min
3.95
Max
4.16
Income | 32M -29M |
|---|---|
Sales | 28M 39M |
EPS | -2.84 |
Profit margin | -74.536 |
Employees | 248 |
EBITDA | 31M -9M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +44.23% upside |
Market Cap | -3K 38M |
|---|---|
Previous open | 3.39 |
Previous close | 4.12 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Bluebird Bio Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Bluebird Bio Inc Forecast
Price Target
By TipRanks
44.23% upside
12 Months Forecast
Average 6 USD 44.23%
High 8 USD
Low 5 USD
Based on 4 Wall Street analysts offering 12 month price targets forBluebird Bio Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bluebird Bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
